News
YMAB
15.00
-0.73%
-0.11
New Strong Buy Stocks for April 17th
NASDAQ · 2d ago
Weekly Report: what happened at YMAB last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at YMAB last week (0401-0405)?
Weekly Report · 04/08 09:08
Y-mAbs Therapeutics Insiders Who Sold Avert US$91m Market Cap Dip
Insiders at Y-mAbs Therapeutics, Inc. Sold US$1.9m worth of stock in the last year. The company's market value decreased by US$91m over the past week. The biggest insider sale was by Thomas Gad, for US$6.24 per share. In the last three months, there was significant insider selling at y-m abs Therapeutic. Insiders in Y- mAbs TherAPEutics didn't buy any shares in the past year. Y-labsTherapeutics insiders own about 3.1% of the company. It's important to check how many shares they own.
Simply Wall St · 04/04 11:31
Y-mAbs Therapeutics Down Nearly 11%, on Pace for Largest Percent Decrease Since November 2022 -- Data Talk
Y-mAbs Therapeutics, Inc. Is currently at $14.42, down $1.77 or 10.93% -- Would be lowest close since March 18, 2024. Currently down six of the past seven days. Down 73.42% from its all-time closing high of $54.26.
Dow Jones · 04/02 18:04
Weekly Report: what happened at YMAB last week (0325-0329)?
Weekly Report · 04/01 09:08
Weekly Report: what happened at YMAB last week (0318-0322)?
Weekly Report · 03/25 09:08
LIVE MARKETS-Big pharma's FOMO will lead to more radio M&A
Big pharma's FOMO will lead to more radio M&A, says Truist Securities. AstraZeneca's $2.4 billion deal to buy Fusion Pharmaceuticals is latest example of renaissance of radio-pharmaceutical drugs. Interest in the space has re-surged since 2011.
Reuters · 03/20 13:33
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
NASDAQ · 03/20 11:37
Weekly Report: what happened at YMAB last week (0311-0315)?
Weekly Report · 03/18 09:08
BUZZ-U.S. STOCKS ON THE MOVE-G-III Apparel Group, Tesla, MicroStrategy
G-III Apparel Group, Tesla, MicroStrategy and United States Steel fall on Thursday. The Dow Jones Industrial Average was down 0.48% and the S&P 500 and Nasdaq Composite also fell. Wall Street's main indexes slipped on Thursday after hotter-than-expected producer prices data.
Reuters · 03/14 18:02
BUZZ-U.S. STOCKS ON THE MOVE-Robinhood Markets, ADM, Vaalco Energy
Dow Jones Industrial Average down 0.25%, S&P 500 and Nasdaq Composite also down. Producer prices data comes in hotter than expected. Build-A-Bear Workshop, ADM and Under Armour rise after strong quarterly results. Robinhood Markets, Netflix and GIII Apparel all rise.
Reuters · 03/14 16:13
BUZZ-Y-mAbs Therapeutics falls after CFO steps down
Shares of drugmaker Y-mAbs Therapeutics fall 6% to $14.88. Company announces resignation of Chief Financial Officer Bo Kruse. Kruse has been in the role since the company's founding in April 2015. The stock has more than doubled in the last 12 months.
Reuters · 03/14 14:36
Y-mAbs Therapeutics CFO Bo Kruse To Retire
NASDAQ · 03/14 13:41
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
TipRanks · 03/14 13:33
Y-mAbs Therapeutics Finance Chief Bo Kruse Resigns
Y-mAbs Therapeutics' top finance executive, Bo Kruse, is leaving the company. Kruse is resigning as chief financial officer. He will remain in his post until the company hires a successor. The company says Kruse will continue as a non-executive employee.
Dow Jones · 03/14 13:19
Y-mAbs Therapeutics says CFO Kruse will resign from his role
Y-mAbs Therapeutics says CFO Kruse will resign from his role. The company added it has commenced a search process for a successor to Bo Kruse. Kruse has been in the role for nine years and will remain in the CFO role until a successor is found.
Seeking Alpha · 03/14 13:08
Y-mAbs Therapeutics Announces Resignation Of Chief Financial Officer, Bo Kruse, Will Remain In The Role Until His Successor Is Identified And Joins The Company
Y-mAbs Therapeutics, Inc. Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. The company is focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer. The Company has commenced a search process for a successor. Mr. Kruse will remain in the Chief Financial officer role until his successor joins the Company.
Benzinga · 03/14 13:06
*Y-mAbs Therapeutics: Kruse Will Remain in the Chief Fincl Officer Role Until His Successor Is Identified and Joins the Co >YMAB
Dow Jones · 03/14 13:06
*Y-mAbs Therapeutics Has Commenced a Search Process for a Successor >YMAB
Dow Jones · 03/14 13:06
More
Webull provides a variety of real-time YMAB stock news. You can receive the latest news about Y-Mabs Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About YMAB
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.